# Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

> **NCT03283371** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 67 (actual)

## Conditions studied

- Epilepsy, Focal Seizures, Partial Seizures

## Interventions

- **DRUG:** Natalizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03283371
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2020-01-11
- **Final completion:** 2020-11-18
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283371, "Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03283371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*